

# Anthony E Lang

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/11819126/anthony-e-lang-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

551  
papers

56,220  
citations

108  
h-index

226  
g-index

573  
ext. papers

66,767  
ext. citations

7.9  
avg, IF

7.9  
L-index

#	Paper	IF	Citations
551	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. <i>Movement Disorders</i> , <b>2008</b> , 23, 2129-70	7	3156
550	Parkinson's disease. <i>Lancet, The</i> , <b>2015</b> , 386, 896-912	40	2652
549	MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , <b>2015</b> , 30, 1591-601	7	2371
548	Parkinson disease. <i>Nature Reviews Disease Primers</i> , <b>2017</b> , 3, 17013	51.1	1700
547	Parkinson's disease. First of two parts. <i>New England Journal of Medicine</i> , <b>1998</b> , 339, 1044-53	59.2	1636
546	A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. <i>New England Journal of Medicine</i> , <b>2000</b> , 342, 1484-91	59.2	1253
545	Phenomenology and classification of dystonia: a consensus update. <i>Movement Disorders</i> , <b>2013</b> , 28, 863-73	7	1217
544	Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. <i>Lancet Neurology, The</i> , <b>2008</b> , 7, 583-90	24.1	1075
543	Criteria for the diagnosis of corticobasal degeneration. <i>Neurology</i> , <b>2013</b> , 80, 496-503	6.5	1004
542	Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. <i>Archives of Neurology</i> , <b>2010</b> , 67, 589-95		988
541	Parkinson's disease. Second of two parts. <i>New England Journal of Medicine</i> , <b>1998</b> , 339, 1130-43	59.2	972
540	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , <b>2017</b> , 32, 853-864	7	840
539	Pharmacological treatment of Parkinson disease: a review. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 311, 1670-83	27.4	816
538	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. <i>Movement Disorders</i> , <b>2007</b> , 22, 41-7	7	802
537	Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. <i>Annals of Neurology</i> , <b>2006</b> , 59, 459-66	9.4	785
536	Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. <i>Annals of Neurology</i> , <b>2003</b> , 54, 93-101	9.4	691
535	Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. <i>Movement Disorders</i> , <b>2006</b> , 21 Suppl 14, S290-304	7	651

534	MDS research criteria for prodromal Parkinson's disease. <i>Movement Disorders</i> , <b>2015</b> , 30, 1600-11	7	645
533	Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. <i>Brain</i> , <b>2002</b> , 125, 1196-209	11.2	545
532	Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. <i>Annals of Neurology</i> , <b>2003</b> , 54 Suppl 5, S15-9	9.4	423
531	Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease. <i>Journal of Neurophysiology</i> , <b>2006</b> , 96, 3248-56	3.2	413
530	Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. <i>JAMA - Journal of the American Medical Association</i> , <b>2002</b> , 287, 455-63	27.4	408
529	Posteroventral medial pallidotomy in advanced Parkinson's disease. <i>New England Journal of Medicine</i> , <b>1997</b> , 337, 1036-42	59.2	392
528	A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. <i>Brain</i> , <b>2008</b> , 131, 2720-8	11.2	392
527	Globus pallidus internus pallidotomy for generalized dystonia. <i>Movement Disorders</i> , <b>1997</b> , 12, 865-70	7	329
526	Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. <i>Neurology</i> , <b>2006</b> , 66, 845-51	6.5	328
525	Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. <i>Movement Disorders</i> , <b>2010</b> , 25, 578-86	7	319
524	Technology in Parkinson's disease: Challenges and opportunities. <i>Movement Disorders</i> , <b>2016</b> , 31, 1272-82		305
523	Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. <i>Archives of Neurology</i> , <b>2011</b> , 68, 1550-6		304
522	Impulse control disorders in Parkinson disease: a multicenter case-control study. <i>Annals of Neurology</i> , <b>2011</b> , 69, 986-96	9.4	296
521	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. <i>Movement Disorders</i> , <b>2014</b> , 29, 454-62	7	290
520	Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. <i>Archives of Neurology</i> , <b>2007</b> , 64, 212-6		289
519	Long-term hardware-related complications of deep brain stimulation. <i>Neurosurgery</i> , <b>2002</b> , 50, 1268-74; discussion 1274-6	3.2	272
518	Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. <i>Annals of Neurology</i> , <b>2010</b> , 68, 18-27	9.4	270
517	Urate as a predictor of the rate of clinical decline in Parkinson disease. <i>Archives of Neurology</i> , <b>2009</b> , 66, 1460-8		265

516	Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. <i>Journal of Neurosurgery</i> , <b>2003</b> , 99, 489-95	3.2	257
515	Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. <i>Lancet Neurology</i> , <b>2004</b> , 3, 309-16	24.1	256
514	Current Concepts in Diagnosis and Treatment of Functional Neurological Disorders. <i>JAMA Neurology</i> , <b>2018</b> , 75, 1132-1141	17.2	252
513	Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. <i>Archives of Neurology</i> , <b>2008</b> , 65, 716-23		251
512	Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. <i>Brain</i> , <b>2006</b> , 129, 1059-69.2		250
511	Deciphering the role of heterozygous mutations in genes associated with parkinsonism. <i>Lancet Neurology</i> , <b>2007</b> , 6, 652-62	24.1	242
510	Long-term follow-up of unilateral pallidotomy in advanced Parkinson's disease. <i>New England Journal of Medicine</i> , <b>2000</b> , 342, 1708-14	59.2	239
509	Mutations in GNAL cause primary torsion dystonia. <i>Nature Genetics</i> , <b>2013</b> , 45, 88-92	36.3	229
508	Neuropsychological outcome of GPi pallidotomy and GPi or STN deep brain stimulation in Parkinson's disease. <i>Brain and Cognition</i> , <b>2000</b> , 42, 324-47	2.7	229
507	Primary dystonia is more responsive than secondary dystonia to pallidal interventions: outcome after pallidotomy or pallidal deep brain stimulation. <i>Neurosurgery</i> , <b>2004</b> , 54, 613-19; discussion 619-21	3.2	224
506	Pallidal neuronal activity: implications for models of dystonia. <i>Annals of Neurology</i> , <b>2003</b> , 53, 480-8	9.4	223
505	Localization of clinically effective stimulating electrodes in the human subthalamic nucleus on magnetic resonance imaging. <i>Journal of Neurosurgery</i> , <b>2002</b> , 97, 1152-66	3.2	222
504	A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. <i>Movement Disorders</i> , <b>2008</b> , 23, 297-9	7	221
503	Short and long latency afferent inhibition in Parkinson's disease. <i>Brain</i> , <b>2003</b> , 126, 1883-94	11.2	214
502	Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. <i>Lancet Neurology</i> , <b>2017</b> , 16, 552-563	24.1	209
501	αSynuclein oligomers and clinical implications for Parkinson disease. <i>Annals of Neurology</i> , <b>2013</b> , 73, 155-69.4		209
500	Deep brain stimulation: preoperative issues. <i>Movement Disorders</i> , <b>2006</b> , 21 Suppl 14, S171-96	7	208
499	Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. <i>Movement Disorders</i> , <b>2004</b> , 19, 656-62	7	208

498	Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. <i>Movement Disorders</i> , <b>2006</b> , 21, 1941-6	7	207
497	Psychogenic movement disorders. <i>Current Opinion in Neurology</i> , <b>2009</b> , 22, 430-6	7.1	205
496	Interface between tauopathies and synucleinopathies: a tale of two proteins. <i>Annals of Neurology</i> , <b>2006</b> , 59, 449-58	9.4	204
495	Apraxia in movement disorders. <i>Brain</i> , <b>2005</b> , 128, 1480-97	11.2	201
494	Stimulation of the subthalamic nucleus and impulsivity: release your horses. <i>Annals of Neurology</i> , <b>2009</b> , 66, 817-24	9.4	199
493	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. <i>Lancet Neurology, The</i> , <b>2014</b> , 13, 676-85	24.1	197
492	Caffeine for treatment of Parkinson disease: a randomized controlled trial. <i>Neurology</i> , <b>2012</b> , 79, 651-8	6.5	197
491	Long-term Hardware-related Complications of Deep Brain Stimulation. <i>Neurosurgery</i> , <b>2002</b> , 50, 1268-1276	6.2	196
490	Distribution, type, and origin of Parkin mutations: review and case studies. <i>Movement Disorders</i> , <b>2004</b> , 19, 1146-57	7	194
489	Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. <i>JAMA Neurology</i> , <b>2015</b> , 72, 100-5	17.2	191
488	Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. <i>Annals of Neurology</i> , <b>2015</b> , 78, 248-57	9.4	190
487	Globus pallidus stimulation activates the cortical motor system during alleviation of parkinsonian symptoms. <i>Nature Medicine</i> , <b>1997</b> , 3, 671-4	50.5	184
486	Bilateral globus pallidus stimulation for Huntington's disease. <i>Annals of Neurology</i> , <b>2004</b> , 56, 290-4	9.4	179
485	Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export. <i>Nature Genetics</i> , <b>2015</b> , 47, 579-81	36.3	176
484	Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations. <i>Movement Disorders</i> , <b>2018</b> , 33, 660-677	7	174
483	Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. <i>Movement Disorders</i> , <b>2007</b> , 22, 2409-17	7	174
482	Long-term follow-up of thalamic deep brain stimulation for essential and parkinsonian tremor. <i>Neurology</i> , <b>2003</b> , 61, 1601-4	6.5	174
481	Hemiballism: revisiting a classic disorder. <i>Lancet Neurology, The</i> , <b>2003</b> , 2, 661-8	24.1	173

480	Cortical and spinal abnormalities in psychogenic dystonia. <i>Annals of Neurology</i> , <b>2006</b> , 59, 825-34	9.4	169
479	Parkinsonian syndromes associated with hydrocephalus: case reports, a review of the literature, and pathophysiological hypotheses. <i>Movement Disorders</i> , <b>1994</b> , 9, 508-20	7	168
478	Chorein detection for the diagnosis of chorea-acanthocytosis. <i>Annals of Neurology</i> , <b>2004</b> , 56, 299-302	9.4	162
477	Deep brain stimulation for Parkinson's disease dissociates mood and motor circuits: a functional MRI case study. <i>Movement Disorders</i> , <b>2003</b> , 18, 1508-16	7	160
476	Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. <i>Movement Disorders</i> , <b>2002</b> , 17, 303-12	7	159
475	The prion hypothesis in Parkinson's disease: Braak to the future. <i>Acta Neuropathologica Communications</i> , <b>2013</b> , 1, 2	7.3	155
474	Practical guidelines for managing adults with 22q11.2 deletion syndrome. <i>Genetics in Medicine</i> , <b>2015</b> , 17, 599-609	8.1	154
473	Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. <i>Neurology</i> , <b>2013</b> , 80, 1698-701	6.5	152
472	Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. <i>Archives of Neurology</i> , <b>2004</b> , 61, 97-102		152
471	Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. <i>Movement Disorders</i> , <b>2015</b> , 30, 500-9	7	151
470	Teaching tape for the motor section of the Toronto Western Spasmodic Torticollis Scale. <i>Movement Disorders</i> , <b>1997</b> , 12, 570-5	7	147
469	Disease-modifying strategies for Parkinson's disease. <i>Movement Disorders</i> , <b>2015</b> , 30, 1442-50	7	146
468	Predicting motor decline and disability in Parkinson disease: a systematic review. <i>Archives of Neurology</i> , <b>2002</b> , 59, 1724-8		146
467	Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 315-324	59.2	145
466	Crossroads in GDNF therapy for Parkinson's disease. <i>Movement Disorders</i> , <b>2006</b> , 21, 136-41	7	145
465	The fragile X premutation presenting as essential tremor. <i>Archives of Neurology</i> , <b>2003</b> , 60, 117-21		145
464	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. <i>Neurology</i> , <b>2019</b> , 92, 329-337	6.5	144
463	Lidocaine and muscimol microinjections in subthalamic nucleus reverse Parkinsonian symptoms. <i>Brain</i> , <b>2001</b> , 124, 2105-18	11.2	141

462	Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. <i>Archives of Neurology</i> , <b>2004</b> , 61, 1898-904		131
461	Overview of the extranigral aspects of Parkinson disease. <i>Archives of Neurology</i> , <b>2009</b> , 66, 167-72		128
460	Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?. <i>Neuropsychopharmacology</i> , <b>2009</b> , 34, 2758-66	8.7	126
459	Relationship of lesion location to clinical outcome following microelectrode-guided pallidotomy for Parkinson's disease. <i>Brain</i> , <b>1999</b> , 122 ( Pt 3), 405-16	11.2	122
458	Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts. <i>Annals of Neurology</i> , <b>2018</b> , 84, 797-811	9.4	122
457	Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts. <i>Translational Neurodegeneration</i> , <b>2017</b> , 6, 8	10.3	121
456	Deep brain stimulation for Parkinson's disease: patient selection and evaluation. <i>Movement Disorders</i> , <b>2002</b> , 17 Suppl 3, S94-101	7	121
455	Psychogenic dystonia: a review of 18 cases. <i>Canadian Journal of Neurological Sciences</i> , <b>1995</b> , 22, 136-43	1	118
454	Opinions and clinical practices related to diagnosing and managing patients with psychogenic movement disorders: An international survey of movement disorder society members. <i>Movement Disorders</i> , <b>2009</b> , 24, 1366-74	7	117
453	Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. <i>Movement Disorders</i> , <b>2006</b> , 21, 1844-50		116
452	Parkinson disease in 2015: Evolving basic, pathological and clinical concepts in PD. <i>Nature Reviews Neurology</i> , <b>2016</b> , 12, 65-6	15	113
451	Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. <i>Movement Disorders</i> , <b>2017</b> , 32, 319-324	7	111
450	Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. <i>Neurogenetics</i> , <b>2013</b> , 14, 11-22	3	111
449	Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. <i>Neurology</i> , <b>2015</b> , 84, 609-16	6.5	110
448	Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. <i>Movement Disorders</i> , <b>2008</b> , 23, 653-9; quiz 776	7	109
447	Neuronal firing rates and patterns in the globus pallidus internus of patients with cervical dystonia differ from those with Parkinson's disease. <i>Journal of Neurophysiology</i> , <b>2007</b> , 98, 720-9	3.2	109
446	Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. <i>Neurology</i> , <b>2014</b> , 82, 1791-7	6.5	108
445	Premotor Parkinson's disease: concepts and definitions. <i>Movement Disorders</i> , <b>2012</b> , 27, 608-16	7	108



444	Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. <i>Lancet Neurology, The</i> , <b>2013</b> , 12, 514-24	24.1	108
443	Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil. <i>Clinical Neuropharmacology</i> , <b>2002</b> , 25, 111-4	1.4	108
442	AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. <i>Movement Disorders</i> , <b>2013</b> , 28, 1838-46	7	107
441	Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications. <i>JAMA Neurology</i> , <b>2013</b> , 70, 1359-66	17.2	107
440	Gait abnormalities in psychogenic movement disorders. <i>Movement Disorders</i> , <b>2007</b> , 22, 395-9	7	107
439	Progressive ataxia and palatal tremor (PAPT): clinical and MRI assessment with review of palatal tremors. <i>Brain</i> , <b>2004</b> , 127, 1252-68	11.2	107
438	Uncovering the role of the insula in non-motor symptoms of Parkinson's disease. <i>Brain</i> , <b>2014</b> , 137, 2143-54	14.2	106
437	Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. <i>Annals of Neurology</i> , <b>2010</b> , 68, 963-8	9.4	105
436	Precision medicine for disease modification in Parkinson disease. <i>Nature Reviews Neurology</i> , <b>2017</b> , 13, 119-126	15	103
435	The nonmotor symptoms of Parkinson's disease--an overview. <i>Movement Disorders</i> , <b>2010</b> , 25 Suppl 1, S123-30	7	103
434	Punding prevalence in Parkinson's disease. <i>Movement Disorders</i> , <b>2007</b> , 22, 1179-81	7	102
433	Antidepressant treatment outcomes of psychogenic movement disorder. <i>Journal of Clinical Psychiatry</i> , <b>2005</b> , 66, 1529-34	4.6	102
432	Validation of the MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , <b>2018</b> , 33, 1601-1608	7	101
431	From psychogenic movement disorder to functional movement disorder: it's time to change the name. <i>Movement Disorders</i> , <b>2014</b> , 29, 849-52	7	101
430	Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study. <i>Neurobiology of Disease</i> , <b>2012</b> , 48, 519-25	7.5	101
429	A critical appraisal of the premotor symptoms of Parkinson's disease: potential usefulness in early diagnosis and design of neuroprotective trials. <i>Movement Disorders</i> , <b>2011</b> , 26, 775-83	7	101
428	The nature and time course of cortical activation following subthalamic stimulation in Parkinson's disease. <i>Cerebral Cortex</i> , <b>2010</b> , 20, 1926-36	5.1	100
427	Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts. <i>Lancet Neurology, The</i> , <b>2017</b> , 16, 620-629	24.1	98



426	Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment. <i>Brain</i> , <b>2014</b> , 137, 565-75	11.2	98
425	Whispering dysphonia (DYT4 dystonia) is caused by a mutation in the TUBB4 gene. <i>Annals of Neurology</i> , <b>2013</b> , 73, 537-45	9.4	98
424	Gut-brain axis and the spread of $\alpha$ -synuclein pathology: Vagal highway or dead end?. <i>Movement Disorders</i> , <b>2019</b> , 34, 307-316	7	98
423	The progression of Parkinson disease: a hypothesis. <i>Neurology</i> , <b>2007</b> , 68, 948-52	6.5	96
422	Deconstructing normal pressure hydrocephalus: Ventriculomegaly as early sign of neurodegeneration. <i>Annals of Neurology</i> , <b>2017</b> , 82, 503-513	9.4	95
421	Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. <i>Movement Disorders</i> , <b>2012</b> , 27, 1392-7	7	94
420	Analysis of the glucocerebrosidase gene in Parkinson's disease. <i>Movement Disorders</i> , <b>2005</b> , 20, 367-70	7	93
419	$\alpha$ -Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era. <i>Trends in Neurosciences</i> , <b>2016</b> , 39, 750-762	13.3	92
418	Non-dopaminergic treatments in development for Parkinson's disease. <i>Lancet Neurology</i> , <b>2008</b> , 7, 927-38	24.1	92
417	Selective enhancement of rapid eye movement sleep by deep brain stimulation of the human pons. <i>Annals of Neurology</i> , <b>2009</b> , 66, 110-4	9.4	91
416	Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure. <i>Movement Disorders</i> , <b>2006</b> , 21, 1578-94	7	91
415	Involvement of human thalamus in the preparation of self-paced movement. <i>Brain</i> , <b>2004</b> , 127, 2717-31	11.2	91
414	Involvement of the cerebellothalamocortical pathway in Parkinson disease. <i>Annals of Neurology</i> , <b>2010</b> , 68, 816-24	9.4	90
413	A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. <i>Movement Disorders</i> , <b>2010</b> , 25, 1077-81	7	90
412	Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. <i>Neurotherapeutics</i> , <b>2014</b> , 11, 6-23	6.4	89
411	Historical and clinical features of psychogenic tremor: a review of 70 cases. <i>Canadian Journal of Neurological Sciences</i> , <b>1999</b> , 26, 190-5	1	89
410	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , <b>2017</b> , 32, 995-1005	7	88
409	Cerebral blood flow changes induced by pedunculopontine nucleus stimulation in patients with advanced Parkinson's disease: a [(15)O] H2O PET study. <i>Human Brain Mapping</i> , <b>2009</b> , 30, 3901-9	5.9	88

408	Interhemispheric and ipsilateral connections in Parkinson's disease: relation to mirror movements. <i>Movement Disorders</i> , <b>2007</b> , 22, 813-21	7	88
407	The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2007</b> , 66, 251-7	3.1	88
406	Placebo effect of medication cost in Parkinson disease: a randomized double-blind study. <i>Neurology</i> , <b>2015</b> , 84, 794-802	6.5	87
405	Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. <i>Movement Disorders</i> , <b>2007</b> , 22, 990-7	7	87
404	Manganese-induced Parkinsonism associated with methcathinone (Ephedrone) abuse. <i>Archives of Neurology</i> , <b>2007</b> , 64, 886-9		87
403	Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2013</b> , 84, 130-5	5.5	86
402	Extrastriatal dopaminergic dysfunction in tourette syndrome. <i>Annals of Neurology</i> , <b>2010</b> , 67, 170-81	9.4	84
401	Investigation of c9orf72 in 4 neurodegenerative disorders. <i>Archives of Neurology</i> , <b>2012</b> , 69, 1583-90		83
400	The cerebellothalamocortical pathway in essential tremor. <i>Neurology</i> , <b>2003</b> , 60, 1985-7	6.5	83
399	Benign hereditary chorea: clinical, genetic, and pathological findings. <i>Annals of Neurology</i> , <b>2003</b> , 54, 244-7	3.4	81
398	Characterization of REM-sleep associated ponto-geniculo-occipital waves in the human pons. <i>Sleep</i> , <b>2007</b> , 30, 823-7	1.1	80
397	Bilateral globus pallidus internus deep brain stimulation in tardive dyskinesia: a case report. <i>Movement Disorders</i> , <b>2004</b> , 19, 969-72	7	80
396	Relationship of lesion location to cognitive outcome following microelectrode-guided pallidotomy for Parkinson's disease: support for the existence of cognitive circuits in the human pallidum. <i>Brain</i> , <b>2000</b> , 123 ( Pt 4), 746-58	11.2	79
395	Phenotype-specific diagnosis of functional (psychogenic) movement disorders. <i>Current Neurology and Neuroscience Reports</i> , <b>2015</b> , 15, 32	6.6	78
394	Helicobacter pylori infection is associated with worse severity of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2015</b> , 21, 221-5	3.6	78
393	A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. <i>Journal of Medical Genetics</i> , <b>2012</b> , 49, 721-6	5.8	78
392	The many faces of corticobasal degeneration. <i>Parkinsonism and Related Disorders</i> , <b>2007</b> , 13 Suppl 3, S336-40	3.40	78
391	Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets. <i>Lancet Neurology</i> , <b>2016</b> , 15, 954-966	24.1	78

390	The treatment of dystonic tremor: a systematic review. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2014</b> , 85, 759-69	5.5	76
389	Stereotypies: a critical appraisal and suggestion of a clinically useful definition. <i>Movement Disorders</i> , <b>2012</b> , 27, 179-85	7	74
388	New developments in understanding the etiology of Parkinson's disease and in its treatment. <i>Current Opinion in Neurobiology</i> , <b>1998</b> , 8, 783-90	7.6	74
387	Corticobasal ganglionic degeneration and progressive supranuclear palsy presenting with cognitive decline. <i>Brain Pathology</i> , <b>1998</b> , 8, 355-65	6	74
386	Psychogenic facial movement disorders: clinical features and associated conditions. <i>Movement Disorders</i> , <b>2012</b> , 27, 1544-51	7	73
385	Unilateral subdural motor cortex stimulation improves essential tremor but not Parkinson's disease. <i>Brain</i> , <b>2011</b> , 134, 2096-105	11.2	73
384	Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. <i>Movement Disorders</i> , <b>2012</b> , 27, 1186-90	7	72
383	Surgery for Parkinson disease: A critical evaluation of the state of the art. <i>Archives of Neurology</i> , <b>2000</b> , 57, 1118-25		72
382	Chronic acquired hepatocerebral degeneration: case reports and new insights. <i>Movement Disorders</i> , <b>1995</b> , 10, 714-22	7	72
381	Management of impulse control disorders in Parkinson's disease: Controversies and future approaches. <i>Movement Disorders</i> , <b>2015</b> , 30, 150-9	7	71
380	Impairments of speed and amplitude of movement in Parkinson's disease: a pilot study. <i>Movement Disorders</i> , <b>2009</b> , 24, 1001-8	7	71
379	Levodopa-related motor complications--phenomenology. <i>Movement Disorders</i> , <b>2008</b> , 23 Suppl 3, S509-14		71
378	Impairment of motor cortex activation and deactivation in Parkinson's disease. <i>Clinical Neurophysiology</i> , <b>2001</b> , 112, 600-7	4.3	71
377	Parietal Pick's disease mimicking cortical-basal ganglionic degeneration. <i>Neurology</i> , <b>1994</b> , 44, 1436-40	6.5	71
376	Dopaminergic transplantation for Parkinson's disease: current status and future prospects. <i>Annals of Neurology</i> , <b>2009</b> , 66, 591-6	9.4	70
375	Caffeine as symptomatic treatment for Parkinson disease (CafEPD): A randomized trial. <i>Neurology</i> , <b>2017</b> , 89, 1795-1803	6.5	69
374	Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. <i>Neurosurgery</i> , <b>2003</b> , 53, 1095-102; discussion 1102-5	3.2	69
373	Pallidal stimulation in Parkinson's disease patients with a prior unilateral pallidotomy. <i>Canadian Journal of Neurological Sciences</i> , <b>1998</b> , 25, 300-5	1	69

372	Posttraumatic painful torticollis. <i>Movement Disorders</i> , <b>2003</b> , 18, 1482-91	7	68
371	Mutation analysis of CHCHD10 in different neurodegenerative diseases. <i>Brain</i> , <b>2015</b> , 138, e380	11.2	67
370	Movement disorder society criteria for clinically established early Parkinson's disease. <i>Movement Disorders</i> , <b>2018</b> , 33, 1643-1646	7	67
369	Imaging Striatal Microglial Activation in Patients with Parkinson's Disease. <i>PLoS ONE</i> , <b>2015</b> , 10, e0138721	3.7	67
368	Psychogenic movement disorders. <i>Canadian Journal of Neurological Sciences</i> , <b>2003</b> , 30 Suppl 1, S94-100	1	67
367	Firing rates of pallidal neurons are similar in Huntington's and Parkinson's disease patients. <i>Experimental Brain Research</i> , <b>2005</b> , 166, 230-6	2.3	66
366	Dopamine Agonists Diminish Value Sensitivity of the Orbitofrontal Cortex: A Trigger for Pathological Gambling in Parkinson's Disease?. <i>Neuropsychopharmacology</i> , <b>2009</b> , 34, 2758-66	8.7	65
365	Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials. <i>Movement Disorders</i> , <b>2016</b> , 31, 538-46	7	65
364	Alimentary, my dear Watson? The challenges of enteric $\alpha$ -synuclein as a Parkinson's disease biomarker. <i>Movement Disorders</i> , <b>2014</b> , 29, 444-50	7	64
363	Vascular Parkinsonism: deconstructing a syndrome. <i>Movement Disorders</i> , <b>2015</b> , 30, 886-94	7	63
362	Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. <i>Nature Medicine</i> , <b>2010</b> , 16, 1223-6	50.5	63
361	Hemiballism in multiple sclerosis. <i>Movement Disorders</i> , <b>1988</b> , 3, 88-94	7	63
360	Salience network and parahippocampal dopamine dysfunction in memory-impaired Parkinson disease. <i>Annals of Neurology</i> , <b>2015</b> , 77, 269-80	9.4	62
359	The new definition and diagnostic criteria of Parkinson's disease. <i>Lancet Neurology</i> , <b>2016</b> , 15, 546-8	24.1	61
358	Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?. <i>Neurology</i> , <b>2020</b> , 94, 481-494	6.5	60
357	Dopamine-agonists and impulsivity in Parkinson's disease: impulsive choices vs. impulsive actions. <i>Human Brain Mapping</i> , <b>2014</b> , 35, 2499-506	5.9	59
356	Movement disorders on YouTube--caveat spectator. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 1160-1	59.2	59
355	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , <b>2019</b> , 34, 1228-1232	7	56

354	Subthalamic nucleus-deep brain stimulation for early motor complications in Parkinson's disease-the EARLYSTIM trial: early is not always better. <i>Movement Disorders</i> , <b>2014</b> , 29, 1751-6	7	56
353	Parkinson's disease in the Western Pacific Region. <i>Lancet Neurology, The</i> , <b>2019</b> , 18, 865-879	24.1	55
352	Criteria for deep-brain stimulation in Parkinson's disease: review and analysis. <i>Expert Review of Neurotherapeutics</i> , <b>2006</b> , 6, 1695-705	4.3	55
351	ATP13A2 variants in early-onset Parkinson's disease patients and controls. <i>Movement Disorders</i> , <b>2009</b> , 24, 2104-11	7	54
350	Involvement of the basal ganglia and cerebellar motor pathways in the preparation of self-initiated and externally triggered movements in humans. <i>Journal of Neuroscience</i> , <b>2007</b> , 27, 6029-36	6.6	54
349	Alterations of striatal neurons in benign hereditary chorea. <i>Movement Disorders</i> , <b>2005</b> , 20, 1353-7	7	54
348	Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects. <i>Movement Disorders</i> , <b>2016</b> , 31, 290-6	7	54
347	Timing of deep brain stimulation in Parkinson disease: a need for reappraisal?. <i>Annals of Neurology</i> , <b>2013</b> , 73, 565-75	9.4	53
346	Peroxisomal D-bifunctional protein deficiency: three adults diagnosed by whole-exome sequencing. <i>Neurology</i> , <b>2014</b> , 82, 963-8	6.5	53
345	Deep brain stimulation for Parkinson's disease. <i>Movement Disorders</i> , <b>2006</b> , 21 Suppl 14, S168-70	7	53
344	Motor neuron disease-inclusion dementia presenting as cortical-basal ganglionic degeneration. <i>Movement Disorders</i> , <b>1999</b> , 14, 674-80	7	53
343	Essential pitfalls in "essential" tremor. <i>Movement Disorders</i> , <b>2017</b> , 32, 325-331	7	52
342	Behavioral effects of levodopa. <i>Movement Disorders</i> , <b>2015</b> , 30, 90-102	7	52
341	Initiation of pharmacological therapy in Parkinson's disease: when, why, and how. <i>Lancet Neurology, The</i> , <b>2020</b> , 19, 452-461	24.1	51
340	Impaired emotion processing in functional (psychogenic) tremor: A functional magnetic resonance imaging study. <i>NeuroImage: Clinical</i> , <b>2018</b> , 17, 179-187	5.3	50
339	Striatonigral degeneration: iron deposition in putamen correlates with the slit-like void signal of magnetic resonance imaging. <i>Canadian Journal of Neurological Sciences</i> , <b>1994</b> , 21, 311-8	1	50
338	Functional neurological disorders in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2018</b> , 89, 566-571	5.5	49
337	Global investigation and meta-analysis of the C9orf72 (G4C2)n repeat in Parkinson disease. <i>Neurology</i> , <b>2014</b> , 83, 1906-13	6.5	49

336	Hereditary parkinsonism: Parkinson disease look-alikes--an algorithm for clinicians to "PARK" genes and beyond. <i>Movement Disorders</i> , <b>2009</b> , 24, 2042-58	7	49
335	Sustained relief of dystonia following cessation of deep brain stimulation. <i>Movement Disorders</i> , <b>2007</b> , 22, 1958-62	7	49
334	'Under pressure': is there a link between orthostatic hypotension and cognitive impairment in Synucleinopathies?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 1311-1321	5.5	49
333	rCBF changes associated with PPN stimulation in a patient with Parkinson's disease: a PET study. <i>Movement Disorders</i> , <b>2008</b> , 23, 1051-1054	7	48
332	Cortical Plasticity Induction by Pairing Subthalamic Nucleus Deep-Brain Stimulation and Primary Motor Cortical Transcranial Magnetic Stimulation in Parkinson's Disease. <i>Journal of Neuroscience</i> , <b>2016</b> , 36, 396-404	6.6	47
331	Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2018</b> , 56, 58-64	3.6	47
330	A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III). <i>Annals of Clinical and Translational Neurology</i> , <b>2017</b> , 4, 360-368	5.3	46
329	When and how should treatment be started in Parkinson disease?. <i>Neurology</i> , <b>2009</b> , 72, S39-43	6.5	46
328	Tics and functional tic-like movements: Can we tell them apart?. <i>Neurology</i> , <b>2019</b> , 93, 750-758	6.5	45
327	Fatigue in Parkinson's disease: report from a multidisciplinary symposium. <i>Npj Parkinsons Disease</i> , <b>2016</b> , 2,	9.7	45
326	Trial designs used to study neuroprotective therapy in Parkinson's disease. <i>Movement Disorders</i> , <b>2013</b> , 28, 86-95	7	45
325	The Ontario Neurodegenerative Disease Research Initiative (ONDRI). <i>Canadian Journal of Neurological Sciences</i> , <b>2017</b> , 44, 196-202	1	44
324	Response to clozapine in a clinically identifiable subtype of schizophrenia. <i>British Journal of Psychiatry</i> , <b>2015</b> , 206, 484-91	5.4	44
323	Antecollis and levodopa-responsive parkinsonism are late features of Dravet syndrome. <i>Neurology</i> , <b>2014</b> , 82, 2250-1	6.5	44
322	A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. <i>Movement Disorders</i> , <b>2009</b> , 24, 2081-90	7	44
321	New use for an old drug: amantadine benefits levodopa-induced dyskinesia. <i>Movement Disorders</i> , <b>1998</b> , 13, 851	7	44
320	Single pulse stimulation of the human subthalamic nucleus facilitates the motor cortex at short intervals. <i>Journal of Neurophysiology</i> , <b>2004</b> , 92, 1937-43	3.2	44
319	Long-term double-blinded unilateral pedunculopontine area stimulation in Parkinson's disease. <i>Movement Disorders</i> , <b>2016</b> , 31, 1570-1574	7	44

3 <sup>18</sup>	Clinical and neural responses to cognitive behavioral therapy for functional tremor. <i>Neurology</i> , <b>2019</b> , 93, e1787-e1798	6.5	43
3 <sup>17</sup>	Movement disorders and other motor abnormalities in adults with 22q11.2 deletion syndrome. <i>American Journal of Medical Genetics, Part A</i> , <b>2015</b> , 167A, 639-45	2.5	43
3 <sup>16</sup>	Benign hereditary chorea revisited: a journey to understanding. <i>Movement Disorders</i> , <b>2007</b> , 22, 2297-305; quiz 2452	7	43
3 <sup>15</sup>	Subthalamic nucleus deep brain stimulation for parkinson's disease after successful pallidotomy: clinical and electrophysiological observations. <i>Movement Disorders</i> , <b>2004</b> , 19, 1209-14	7	43
3 <sup>14</sup>	Myoclonus-dystonia: classification, phenomenology, pathogenesis, and treatment. <i>Current Opinion in Neurology</i> , <b>2018</b> , 31, 484-490	7.1	43
3 <sup>13</sup>	Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities. <i>Translational Neurodegeneration</i> , <b>2019</b> , 8, 28	10.3	42
3 <sup>12</sup>	Reproducibility of data-driven Parkinson's disease subtypes for clinical research. <i>Parkinsonism and Related Disorders</i> , <b>2018</b> , 56, 102-106	3.6	42
3 <sup>11</sup>	Characteristic head drops and axial extension in advanced chorea-acanthocytosis. <i>Movement Disorders</i> , <b>2010</b> , 25, 1487-91	7	42
3 <sup>10</sup>	Neuropsychological and behavioral changes and weight gain after medial pallidotomy. <i>Annals of Neurology</i> , <b>1997</b> , 41, 834-6	9.4	42
3 <sup>09</sup>	Deep brain stimulator electrodes used for lesioning: proof of principle. <i>Neurosurgery</i> , <b>2001</b> , 49, 363-7; discussion 367-9	3.2	42
3 <sup>08</sup>	Anticholinergics in adult-onset focal dystonia. <i>Canadian Journal of Neurological Sciences</i> , <b>1982</b> , 9, 313-9	1	42
3 <sup>07</sup>	Caffeine consumption and risk of dyskinesia in CALM-PD. <i>Movement Disorders</i> , <b>2013</b> , 28, 380-3	7	41
3 <sup>06</sup>	Psychogenic movement disorders. <i>Current Opinion in Neurology</i> , <b>2005</b> , 18, 399-404	7.1	41
3 <sup>05</sup>	Psychiatric symptoms in patients with Parkinson disease presenting for deep brain stimulation surgery. <i>Journal of Neurosurgery</i> , <b>2005</b> , 103, 246-51	3.2	41
3 <sup>04</sup>	Persistent hemiballismus with lesions outside the subthalamic nucleus. <i>Canadian Journal of Neurological Sciences</i> , <b>1985</b> , 12, 125-8	1	41
3 <sup>03</sup>	Common Myths in the Use of Levodopa in Parkinson Disease: When Clinical Trials Misinform Clinical Practice. <i>JAMA Neurology</i> , <b>2017</b> , 74, 633-634	17.2	40
3 <sup>02</sup>	Motor Phenotype in Neurodegenerative Disorders: Gait and Balance Platform Study Design Protocol for the Ontario Neurodegenerative Research Initiative (ONDRI). <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 59, 707-721	4.3	40
3 <sup>01</sup>	Pallidotomy for Parkinson's Disease. <i>Neurosurgery Clinics of North America</i> , <b>1998</b> , 9, 325-336	4	40



300	Positron emission tomography imaging of tau pathology in progressive supranuclear palsy. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2017</b> , 37, 3150-3160	7.3	38
299	Psychogenic movement disorders: past developments, current status, and future directions. <i>Movement Disorders</i> , <b>2011</b> , 26, 1175-86	7	38
298	Refinement of the DYT15 locus in myoclonus dystonia. <i>Movement Disorders</i> , <b>2007</b> , 22, 888-92	7	38
297	Appendectomy in mid and later life and risk of Parkinson's disease: A population-based study. <i>Movement Disorders</i> , <b>2016</b> , 31, 1243-7	7	38
296	Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study. <i>Brain</i> , <b>2016</b> , 139, 2050-62	11.2	38
295	Parkinson Diseases in the 2020s and Beyond: Replacing Clinico-Pathologic Convergence With Systems Biology Divergence. <i>Journal of Parkinson's Disease</i> , <b>2018</b> , 8, S59-S64	5.3	38
294	Dystonia and Parkinson's disease: What is the relationship?. <i>Neurobiology of Disease</i> , <b>2019</b> , 132, 104462	7.5	37
293	Outcome measurement in functional neurological disorder: a systematic review and recommendations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2020</b> , 91, 638-649	5.5	37
292	Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. <i>Lancet Neurology, The</i> , <b>2012</b> , 11, 643-50	24.1	37
291	Pallidal deep brain stimulation modulates cortical excitability and plasticity. <i>Annals of Neurology</i> , <b>2018</b> , 83, 352-362	9.4	36
290	Associated movement disorders in orthostatic tremor. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2012</b> , 83, 725-9	5.5	36
289	Impact of mild cognitive impairment on health-related quality of life in Parkinson's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2013</b> , 36, 67-75	2.6	36
288	Motor cortical stimulation for parkinsonism in multiple system atrophy. <i>Archives of Neurology</i> , <b>2003</b> , 60, 1554-8		36
287	Imaging changes associated with cognitive abnormalities in Parkinson's disease. <i>Brain Structure and Function</i> , <b>2015</b> , 220, 2249-61	4	35
286	Unusual tremor syndromes: know in order to recognise. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 1191-1203	5.5	35
285	Perioperative problems in Parkinson's disease and their management: apomorphine with rectal domperidone. <i>Canadian Journal of Neurological Sciences</i> , <b>1996</b> , 23, 198-203	1	35
284	Disrupted Nodal and Hub Organization Account for Brain Network Abnormalities in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , <b>2016</b> , 8, 259	5.3	35
283	Abolishing the 1-year rule: How much evidence will be enough?. <i>Movement Disorders</i> , <b>2016</b> , 31, 1623-1627		35

282	Effects of subthalamic nucleus stimulation on motor cortex plasticity in Parkinson disease. <i>Neurology</i> , <b>2015</b> , 85, 425-32	6.5	34
281	Altered gut microbiome and metabolome in patients with multiple system atrophy. <i>Movement Disorders</i> , <b>2018</b> , 33, 174-176	7	34
280	Emotion Detection Deficits and Decreased Empathy in Patients with Alzheimer's Disease and Parkinson's Disease Affect Caregiver Mood and Burden. <i>Frontiers in Aging Neuroscience</i> , <b>2018</b> , 10, 120	5.3	34
279	Acquired neurosyphilis presenting as movement disorders. <i>Movement Disorders</i> , <b>2012</b> , 27, 690-5	7	34
278	The curious case of phenocopies in families with genetic Parkinson's disease. <i>Movement Disorders</i> , <b>2011</b> , 26, 1793-802	7	34
277	The spectrum of orolingual tremor--a proposed classification system. <i>Movement Disorders</i> , <b>2008</b> , 23, 159-67	7	34
276	Electrophysiological features of myoclonus-dystonia. <i>Movement Disorders</i> , <b>2008</b> , 23, 2055-61	7	34
275	Corticobasal degeneration: selected developments. <i>Movement Disorders</i> , <b>2003</b> , 18 Suppl 6, S51-6	7	34
274	Variability in lesion location after microelectrode-guided pallidotomy for Parkinson's disease: anatomical, physiological, and technical factors that determine lesion distribution. <i>Journal of Neurosurgery</i> , <b>1999</b> , 90, 468-77	3.2	34
273	Treatment of Parkinson's disease with agents other than levodopa and dopamine agonists: controversies and new approaches. <i>Canadian Journal of Neurological Sciences</i> , <b>1984</b> , 11, 210-20	1	34
272	Gut Microbial Ecosystem in Parkinson Disease: New Clinicobiological Insights from Multi-Omics. <i>Annals of Neurology</i> , <b>2021</b> , 89, 546-559	9.4	34
271	Essential tremor plus is more common than essential tremor: Insights from the reclassification of a cohort of patients with lower limb tremor. <i>Parkinsonism and Related Disorders</i> , <b>2018</b> , 56, 109-110	3.6	33
270	Surgical correction of kyphosis in patients with camptocormia due to Parkinson's disease: a retrospective evaluation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2011</b> , 82, 364-8	5.5	33
269	High dose anticholinergic therapy in adult dystonia. <i>Canadian Journal of Neurological Sciences</i> , <b>1986</b> , 13, 42-6	1	33
268	Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses. <i>Neurology</i> , <b>2014</b> , 82, 1402-9	6.5	32
267	Pardoprinox in early Parkinson's disease: results from 2 large, randomized double-blind trials. <i>Movement Disorders</i> , <b>2011</b> , 26, 1464-76	7	32
266	Caffeine in Parkinson's disease: a pilot open-label, dose-escalation study. <i>Movement Disorders</i> , <b>2011</b> , 26, 2427-31	7	32
265	Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments. <i>Movement Disorders</i> , <b>2013</b> , 28, 1980-6	7	31

264	Deep Brain Stimulator Electrodes Used for Lesioning: Proof of Principle. <i>Neurosurgery</i> , <b>2001</b> , 49, 363-369.	3.2	31
263	Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinson's disease. <i>Brain</i> , <b>2017</b> , 140, 1371-1383	11.2	30
262	Subdural motor cortex stimulation in Parkinson's disease does not modify movement-related rCBF pattern. <i>Movement Disorders</i> , <b>2007</b> , 22, 2113-6	7	30
261	Identification of a VPS13A founder mutation in French Canadian families with chorea-acanthocytosis. <i>Neurogenetics</i> , <b>2005</b> , 6, 151-8	3	30
260	The core assessment program for intracerebral transplantation. <i>Movement Disorders</i> , <b>1995</b> , 10, 527-8	7	30
259	Contribution of insula in Parkinson's disease: A quantitative meta-analysis study. <i>Human Brain Mapping</i> , <b>2016</b> , 37, 1375-92	5.9	30
258	The long-term outcome of orthostatic tremor. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 167-72	5.5	29
257	[F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP. <i>Brain Structure and Function</i> , <b>2018</b> , 223, 589-595	4	29
256	GDNF in treatment of Parkinson's disease: response to editorial. <i>Lancet Neurology</i> , <b>2006</b> , 5, 200-2	24.1	29
255	Withdrawal akathisia: case reports and a proposed classification of chronic akathisia. <i>Movement Disorders</i> , <b>1994</b> , 9, 188-92	7	29
254	Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: the spectrum of hemiparkinsonism-hemiatrophy syndrome. <i>Movement Disorders</i> , <b>1995</b> , 10, 489-95	7	29
253	Probiotics for Constipation in Parkinson Disease: A Randomized Placebo-Controlled Study. <i>Neurology</i> , <b>2021</b> , 96, e772-e782	6.5	29
252	The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age. <i>Movement Disorders</i> , <b>2019</b> , 34, 676-681	7	28
251	GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. <i>Journal of Parkinson's Disease</i> , <b>2020</b> , 10, 875-891	5.3	28
250	What is "essential" about essential tremor? A diagnostic placeholder. <i>Movement Disorders</i> , <b>2018</b> , 33, 58-61	6.1	28
249	Movement disorders in patients with diabetes mellitus. <i>Journal of the Neurological Sciences</i> , <b>2012</b> , 314, 5-11	3.2	28
248	Unilateral versus bilateral tasks in early asymmetric Parkinson's disease: differential effects on bradykinesia. <i>Movement Disorders</i> , <b>2007</b> , 22, 328-33	7	28
247	Neurodegenerative disease and the evolution of art: the effects of presumed corticobasal degeneration in a professional artist. <i>Movement Disorders</i> , <b>2003</b> , 18, 294-302	7	28

246	Genetic association study of PINK1 coding polymorphisms in Parkinson's disease. <i>Neuroscience Letters</i> , <b>2004</b> , 372, 226-9	3.3	28
245	Double-blind study of pramipexole, a new partial dopamine agonist, in early Parkinson's disease. <i>Movement Disorders</i> , <b>2010</b> , 25, 738-46	7	27
244	Gestes antagonistes in psychogenic dystonia. <i>Movement Disorders</i> , <b>2004</b> , 19, 331-2	7	27
243	Natural history of Oppenheim's dystonia (DYT1) in Israel. <i>Journal of Child Neurology</i> , <b>2003</b> , 18, 325-30	2.5	27
242	Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2. <i>Neurology</i> , <b>2018</b> , 90, e2059-e2067	6.5	25
241	What Is the Role of a Specialist Assessment Clinic for FND? Lessons From Three National Referral Centers. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , <b>2020</b> , 32, 79-84	2.7	25
240	Mutation analysis of patients with neurodegenerative disorders using NeuroX array. <i>Neurobiology of Aging</i> , <b>2015</b> , 36, 545.e9-14	5.6	24
239	Orthostatic hypotension, cerebral hypoperfusion, and visuospatial deficits in Lewy body disorders. <i>Parkinsonism and Related Disorders</i> , <b>2016</b> , 22, 80-6	3.6	24
238	The perioperative management of Parkinson's disease revisited. <i>Neurologic Clinics</i> , <b>2004</b> , 22, 367-77	4.5	24
237	Oculogyric crises: A review of phenomenology, etiology, pathogenesis, and treatment. <i>Movement Disorders</i> , <b>2017</b> , 32, 193-202	7	23
236	The value of GRE, ADC and routine MRI in distinguishing Parkinsonian disorders. <i>Canadian Journal of Neurological Sciences</i> , <b>2013</b> , 40, 389-402	1	23
235	Homozygous and heterozygous PINK1 mutations: considerations for diagnosis and care of Parkinson's disease patients. <i>Movement Disorders</i> , <b>2006</b> , 21, 875-9	7	23
234	Clinical findings in a large family with a parkin ex3delta40 mutation. <i>Archives of Neurology</i> , <b>2004</b> , 61, 701-4		23
233	Pallidal deep brain stimulation influences both reflexive and voluntary saccades in Huntington's disease. <i>Movement Disorders</i> , <b>2005</b> , 20, 371-7	7	23
232	Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. <i>Parkinsonism and Related Disorders</i> , <b>2016</b> , 28, 41-48	3.6	23
231	Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies. <i>Movement Disorders</i> , <b>2020</b> , 35, 171-176	7	23
230	'Don't delay, start today': delaying levodopa does not delay motor complications. <i>Brain</i> , <b>2014</b> , 137, 2628-30	3.02	22
229	Antidepressants in the treatment of psychosis with comorbid depression in Parkinson disease. <i>Clinical Neuropharmacology</i> , <b>2004</b> , 27, 90-2	1.4	22

228	Lymphatic vasculature in human dural superior sagittal sinus: Implications for neurodegenerative proteinopathies. <i>Neuroscience Letters</i> , <b>2018</b> , 665, 18-21	3.3	22
227	Adult motor phenotype differentiates Dravet syndrome from Lennox-Gastaut syndrome and links SCN1A to early onset parkinsonian features. <i>Epilepsia</i> , <b>2017</b> , 58, e44-e48	6.4	21
226	Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease. <i>Movement Disorders</i> , <b>2017</b> , 32, 893-903	7	21
225	Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion. <i>Parkinsonism and Related Disorders</i> , <b>2015</b> , 21, 968-71	3.6	21
224	Longitudinal quantitative MRI in multiple system atrophy and progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , <b>2014</b> , 20, 222-5	3.6	21
223	Fatigue in Parkinson's disease: The contribution of cerebral metabolic changes. <i>Human Brain Mapping</i> , <b>2017</b> , 38, 283-292	5.9	21
222	Development of a non-motor fluctuation assessment instrument for Parkinson disease. <i>Parkinson's Disease</i> , <b>2011</b> , 2011, 292719	2.6	21
221	Dystonia in complex regional pain syndrome type I. <i>Annals of Neurology</i> , <b>2010</b> , 67, 412-4	9.4	21
220	Microelectrode recordings define the ventral posteromedial pallidotomy target. <i>Stereotactic and Functional Neurosurgery</i> , <b>1998</b> , 71, 153-63	1.6	21
219	Alpha methylparatyrosine and tetrabenazine in movement disorders. <i>Clinical Neuropharmacology</i> , <b>1982</b> , 5, 375-87	1.4	21
218	Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance. <i>Movement Disorders</i> , <b>2020</b> , 35, 1755-1764	7	21
217	Reduced intracortical and interhemispheric inhibitions in corticobasal syndrome. <i>Journal of Clinical Neurophysiology</i> , <b>2008</b> , 25, 304-12	2.2	20
216	Helicobacter pylori Eradication in Parkinson's Disease: A Randomized Placebo-Controlled Trial. <i>Movement Disorders</i> , <b>2020</b> , 35, 2250-2260	7	20
215	Alternating Hemiplegia of Childhood as a New Presentation of Adenylate Cyclase 5-Mutation-Associated Disease: A Report of Two Cases. <i>Journal of Pediatrics</i> , <b>2017</b> , 181, 306-308.e1	3.6	19
214	Neuroprotection in Parkinson's disease: and now for something completely different?. <i>Lancet Neurology</i> , <b>2006</b> , 5, 990-1	24.1	19
213	Repurposing drugs to treat L-DOPA-induced dyskinesia in Parkinson's disease. <i>Neuropharmacology</i> , <b>2019</b> , 147, 11-27	5.5	18
212	ADCY5-Related Dyskinesia: Improving Clinical Detection of an Evolving Disorder. <i>Movement Disorders Clinical Practice</i> , <b>2019</b> , 6, 512-520	2.2	18
211	Implications of nocturnal symptoms towards the early diagnosis of Parkinson's disease. <i>Journal of Neural Transmission</i> , <b>2014</b> , 121 Suppl 1, S49-57	4.3	18

210	Myoclonus in complex regional pain syndrome. <i>Movement Disorders</i> , <b>2009</b> , 24, 314-6; author reply 316	7	18
209	Antidepressants and psychosis in Parkinson disease: a case series. <i>International Journal of Geriatric Psychiatry</i> , <b>2007</b> , 22, 601-4	3.9	18
208	Association Between Social Cognition Changes and Resting State Functional Connectivity in Frontotemporal Dementia, Alzheimer's Disease, Parkinson's Disease, and Healthy Controls. <i>Frontiers in Neuroscience</i> , <b>2019</b> , 13, 1259	5.1	17
207	Neuronal intranuclear inclusion disease: two cases of dopa-responsive juvenile parkinsonism with drug-induced dyskinesia. <i>Movement Disorders</i> , <b>2010</b> , 25, 1274-9	7	17
206	Standard guidelines for publication of deep brain stimulation studies in Parkinson's disease (Guide4DBS-PD). <i>Movement Disorders</i> , <b>2010</b> , 25, 1530-7	7	17
205	Unique form of propriospinal myoclonus as a possible complication of an enteropathogenic toxin. <i>Movement Disorders</i> , <b>2003</b> , 18, 942-8	7	17
204	Characterization of Movement Disorder Phenomenology in Genetically Proven, Familial Frontotemporal Lobar Degeneration: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , <b>2016</b> , 11, e0153852	3.7	17
203	Pedunculopontine nucleus stimulation in progressive supranuclear palsy: a randomised trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2017</b> , 88, 613-616	5.5	16
202	Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes. <i>Frontiers in Neurology</i> , <b>2020</b> , 11, 572976	4.1	16
201	Levodopa challenge test: indications, protocol, and guide. <i>Journal of Neurology</i> , <b>2021</b> , 268, 3135-3143	5.5	16
200	Unfreezing of gait in patients with Parkinson's disease. <i>Lancet Neurology</i> , <b>2015</b> , 14, 675-7	24.1	16
199	Thalamic neuronal and EMG activity in psychogenic dystonia compared with organic dystonia. <i>Movement Disorders</i> , <b>2011</b> , 26, 1348-52	7	16
198	Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. <i>Movement Disorders</i> , <b>2011</b> , 26, 608-13	7	16
197	Potential placebo effect in assessing idiopathic normal pressure hydrocephalus. <i>Journal of Neurosurgery</i> , <b>2011</b> , 114, 1428-31	3.2	16
196	Long-term effect of unilateral pallidotomy on levodopa-induced dyskinesia. <i>Movement Disorders</i> , <b>2010</b> , 25, 1496-8	7	16
195	What is it? Case 1, 1994: rapidly progressive aphasia, apraxia, dementia, myoclonus, and parkinsonism. <i>Movement Disorders</i> , <b>1994</b> , 9, 358-66	7	16
194	Telemedicine in Movement Disorders: Leçons du COVID-19. <i>Movement Disorders</i> , <b>2020</b> , 35, 1893-1896	7	16
193	Therapeutic trial design for frontotemporal dementia and related disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2019</b> , 90, 412-423	5.5	16



192	Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. <i>Nature Medicine</i> , <b>2021</b> , 27, 1451-1457	50.5	16
191	Mutation analysis of CHCHD2 in Canadian patients with familial Parkinson's disease. <i>Neurobiology of Aging</i> , <b>2016</b> , 38, 217.e7-217.e8	5.6	15
190	Diagnosing psychogenic movement disorders-which criteria should be used in clinical practice?. <i>Nature Clinical Practice Neurology</i> , <b>2007</b> , 3, 134-5		15
189	Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease. <i>Movement Disorders</i> , <b>2017</b> , 32, 610-614	7	14
188	Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy. <i>Journal of Neural Transmission</i> , <b>2018</b> , 125, 1373-1379	4.3	14
187	Designing clinical trials for dystonia. <i>Neurotherapeutics</i> , <b>2014</b> , 11, 117-27	6.4	14
186	Bilateral pallidal stimulation for sargoglycan epsilon negative myoclonus. <i>Parkinsonism and Related Disorders</i> , <b>2014</b> , 20, 915-8	3.6	14
185	Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [(11) C]-(+)-PHNO and [(11) C]raclopride positron emission tomography imaging study. <i>Human Brain Mapping</i> , <b>2015</b> , 36, 2592-601	5.9	14
184	Orthostatic tremor in progressive supranuclear palsy. <i>Movement Disorders</i> , <b>2007</b> , 22, 1192-4	7	14
183	The G2019S LRRK2 mutation in Brazilian patients with Parkinson's disease: phenotype in monozygotic twins. <i>Movement Disorders</i> , <b>2008</b> , 23, 290-4	7	14
182	Idiopathic generalized myokymia (Isaacs' syndrome) with hand posturing resembling dystonia. <i>Movement Disorders</i> , <b>1996</b> , 11, 448-9	7	14
181	Can Isolated Enlarged Virchow-Robin Spaces Influence the Clinical Manifestations of Parkinson's Disease?. <i>Movement Disorders Clinical Practice</i> , <b>2014</b> , 1, 67-69	2.2	13
180	Initiating dopaminergic treatment in Parkinson's disease. <i>Lancet, The</i> , <b>2014</b> , 384, 1164-6	40	13
179	Progressive ataxia and palatal tremor: Two autopsy cases of a novel tauopathy. <i>Movement Disorders</i> , <b>2017</b> , 32, 1465-1473	7	13
178	Pallidotomy for tremor. <i>Movement Disorders</i> , <b>1998</b> , 13 Suppl 3, 107-10	7	13
177	Asymmetric neuromodulation of motor circuits in Parkinson's disease: The role of subthalamic deep brain stimulation. <i>Surgical Neurology International</i> , <b>2017</b> , 8, 261	1	13
176	Hallucinations, Delusions and Impulse Control Disorders in Parkinson Disease. <i>Clinics in Geriatric Medicine</i> , <b>2020</b> , 36, 105-118	3.8	13
175	Clozapine in Parkinsonian Rest Tremor: A Review of Outcomes, Adverse Reactions, and Possible Mechanisms of Action. <i>Movement Disorders Clinical Practice</i> , <b>2016</b> , 3, 116-124	2.2	13



174	Soft signs in movement disorders: friends or foes?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2019</b> , 90, 961-962	5.5	13
173	Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series. <i>American Journal of Medical Genetics, Part A</i> , <b>2018</b> , 176, 2146-2159	2.5	13
172	Clinicopathological review of pallidonigroluysian atrophy. <i>Movement Disorders</i> , <b>2013</b> , 28, 274-81	7	12
171	Functional/psychogenic movement disorders: do we know what they are?. <i>Movement Disorders</i> , <b>2014</b> , 29, 1696-7; discussion 1699-701	7	12
170	Expanding the phenomenology of benign hereditary chorea: evolution from chorea to myoclonus and dystonia. <i>Movement Disorders</i> , <b>2011</b> , 26, 2296-7	7	12
169	Integrated Therapy for Functional Movement Disorders: Time for a Change. <i>Movement Disorders Clinical Practice</i> , <b>2020</b> , 7, 169-174	2.2	12
168	Corticobasal degeneration. <i>International Review of Neurobiology</i> , <b>2019</b> , 149, 87-136	4.4	12
167	The Interaction Between Neuroinflammation and $\beta$ Amyloid in Cognitive Decline in Parkinson's Disease. <i>Molecular Neurobiology</i> , <b>2020</b> , 57, 492-501	6.2	12
166	Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , <b>2018</b> , 8, 503-510	5.3	12
165	Diagnostic delay in Parkinson's disease caused by PRKN mutations. <i>Parkinsonism and Related Disorders</i> , <b>2019</b> , 63, 217-220	3.6	11
164	Hiding in Plain Sight: Functional Neurological Disorders in the News. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , <b>2019</b> , 31, 361-367	2.7	11
163	Paroxysmal Asymmetric Dystonic Arm Posturing-A Less Recognized but Characteristic Manifestation of ATP1A3-related disease. <i>Movement Disorders Clinical Practice</i> , <b>2019</b> , 6, 312-315	2.2	11
162	The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2013</b> , 43, 151-6	5.5	11
161	GDNF in Parkinson's disease: the perils of post-hoc power. <i>Journal of Neuroscience Methods</i> , <b>2007</b> , 163, 193-6	3	11
160	Whole-genome sequencing suggests mechanisms for 22q11.2 deletion-associated Parkinson's disease. <i>PLoS ONE</i> , <b>2017</b> , 12, e0173944	3.7	11
159	Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee. <i>Neurology</i> , <b>2021</b> , 97, 942-957	6.5	11
158	The Logic and Pitfalls of Parkinson's Disease as "Brain-First" Versus "Body-First" Subtypes. <i>Movement Disorders</i> , <b>2021</b> , 36, 594-598	7	11
157	Serum Inflammatory Profile for the Discrimination of Clinical Subtypes in Parkinson's Disease. <i>Frontiers in Neurology</i> , <b>2018</b> , 9, 1123	4.1	11

156	Systematic review of movement disorders and oculomotor abnormalities in Whipple's disease. <i>Movement Disorders</i> , <b>2018</b> , 33, 1700-1711	7	11
155	Action Myoclonus and Seizure in Kufor-Rakeb Syndrome. <i>Movement Disorders Clinical Practice</i> , <b>2018</b> , 5, 195-199	2.2	11
154	Orthostatic hypotension and dementia incidence: links and implications. <i>Neuropsychiatric Disease and Treatment</i> , <b>2019</b> , 15, 2181-2194	3.1	10
153	Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study. <i>Movement Disorders</i> , <b>2018</b> , 33, 960-965	7	10
152	A case of neurosyphilis presenting with myoclonus, cerebellar ataxia, and speech disturbance. <i>Movement Disorders</i> , <b>2012</b> , 27, 794	7	10
151	A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts. <i>Movement Disorders</i> , <b>2009</b> , 24, 2370-8	7	10
150	Reversible dopamine agonist induced anterocollis in a multiple system atrophy patient. <i>Movement Disorders</i> , <b>2007</b> , 22, 2292-3	7	10
149	Rapidly progressive sporadic dentatorubral pallidoluysian atrophy with intracytoplasmic inclusions and no CAG repeat expansion. <i>Movement Disorders</i> , <b>2006</b> , 21, 2251-4	7	10
148	Decreased pallidal vesicular monoamine transporter type 2 availability in Parkinson's disease: The contribution of the nigropallidal pathway. <i>Neurobiology of Disease</i> , <b>2019</b> , 124, 176-182	7.5	10
147	Voxel-based imaging of translocator protein 18 kDa (TSPO) in high-resolution PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2013</b> , 33, 348-50	7.3	9
146	Comprehensive mutational analysis of LRRK2 reveals variants supporting association with autosomal dominant Parkinson's disease. <i>Journal of Human Genetics</i> , <b>2011</b> , 56, 671-5	4.3	9
145	Sporadic case of dentatorubral pallidoluysian atrophy with no CAG repeat expansion and no intranuclear inclusions. <i>Movement Disorders</i> , <b>2004</b> , 19, 580-3	7	9
144	Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease. <i>Annals of Neurology</i> , <b>2021</b> , 90, 76-88	9.4	9
143	Parkinson's Disease, NOTCH3 Genetic Variants, and White Matter Hyperintensities. <i>Movement Disorders</i> , <b>2020</b> , 35, 2090-2095	7	8
142	Genome-wide variant by serum urate interaction in Parkinson's disease. <i>Annals of Neurology</i> , <b>2015</b> , 78, 731-41	9.4	8
141	Event-related desynchronization of motor cortical oscillations in patients with multiple system atrophy. <i>Experimental Brain Research</i> , <b>2010</b> , 206, 1-13	2.3	8
140	Insights into brain function through the examination of art: the influence of neurodegenerative diseases. <i>NeuroReport</i> , <b>2004</b> , 15, 933-7	1.7	8
139	Dancing Dorsal Quadrilaterals: A Novel Peripherally Induced Movement Disorder. <i>JAMA Neurology</i> , <b>2019</b> , 76, 351-354	17.2	8

138	Increased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinson's disease. <i>Clinical Autonomic Research</i> , <b>2019</b> , 29, 603-614	4.3	7
137	Adult-onset neuronal intranuclear inclusion disease mimicking Fragile X-associated tremor-ataxia syndrome in ethnic Chinese patients. <i>Parkinsonism and Related Disorders</i> , <b>2020</b> , 74, 25-27	3.6	7
136	Oculogyric crises in PLA2G6 associated neurodegeneration. <i>Parkinsonism and Related Disorders</i> , <b>2018</b> , 52, 111-112	3.6	7
135	Actigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation Carriers. <i>Journal of Parkinson's Disease</i> , <b>2018</b> , 8, 131-139	5.3	7
134	Successful treatment of functional palatal tremor: Insights into pathogenesis and management. <i>Movement Disorders</i> , <b>2015</b> , 30, 875-6	7	7
133	The classification of akathisia. <i>Movement Disorders</i> , <b>1995</b> , 10, 235-7	7	7
132	Parkinsonism as a Sequela of SARS-CoV-2 Infection: Pure Hypoxic Injury or Additional COVID-19-Related Response?. <i>Movement Disorders</i> , <b>2021</b> , 36, 1483-1484	7	7
131	Sleep-related motor and behavioral disorders: Recent advances and new entities. <i>Movement Disorders</i> , <b>2018</b> , 33, 1042-1055	7	6
130	LRRK2 and Parkin mutations in a family with parkinsonism-Lack of genotype-phenotype correlation. <i>Neurobiology of Aging</i> , <b>2010</b> , 31, 721-2	5.6	6
129	The grasp reflex: a symptom in need of treatment. <i>Movement Disorders</i> , <b>2010</b> , 25, 2479-85	7	6
128	Neuronal activity in the globus pallidus of multiple system atrophy patients. <i>Movement Disorders</i> , <b>2004</b> , 19, 1485-92	7	6
127	Primary brain calcification due to a homozygous MYORG mutation causing isolated paroxysmal kinesigenic dyskinesia. <i>Brain</i> , <b>2020</b> , 143, e36	11.2	6
126	Myoclonus in parkinsonian disorders. <i>Advances in Neurology</i> , <b>2002</b> , 89, 77-83		6
125	Tremor-Dominant Pantothenate Kinase-associated Neurodegeneration. <i>Movement Disorders Clinical Practice</i> , <b>2017</b> , 4, 772-774	2.2	5
124	Placebos in clinical trials: unravelling a complex phenomenon. <i>Lancet Neurology, The</i> , <b>2017</b> , 16, 28-29	24.1	5
123	The clinical significance of lower limb tremors. <i>Parkinsonism and Related Disorders</i> , <b>2019</b> , 65, 165-171	3.6	5
122	PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers. <i>Frontiers in Neurology</i> , <b>2020</b> , 11, 574	4.1	5
121	Educational Needs and Considerations for a Visual Educational Tool to Discuss Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , <b>2018</b> , 5, 66-74	2.2	5

120	Learning More from Finger Tapping in Parkinson's Disease: Up and Down from Dyskinesia to Bradykinesia. <i>Movement Disorders Clinical Practice</i> , <b>2016</b> , 3, 184-187	2.2	5
119	Tremor in Spinocerebellar Ataxia Type 12. <i>Movement Disorders Clinical Practice</i> , <b>2014</b> , 1, 76-78	2.2	5
118	Early-onset tardive dyskinesia in a neuroleptic-naive patient exposed to low-dose quetiapine. <i>Movement Disorders</i> , <b>2011</b> , 26, 2297-8	7	5
117	Fixed dystonia unresponsive to pallidal stimulation improved by motor cortex stimulation. <i>Neurology</i> , <b>2007</b> , 69, 1062-3; author reply 1063	6.5	5
116	Manipulating the dopaminergic system in Parkinson's disease <b>1987</b> , 32, 51-76		5
115	The retina as a window to the basal ganglia: Systematic review of the potential link between retinopathy and hyperkinetic disorders in diabetes. <i>Parkinsonism and Related Disorders</i> , <b>2020</b> , 80, 194-198	3.6	5
114	Paroxysmal Hemiballism/Hemichorea Resulting from Transient Ischemic Attacks. <i>Movement Disorders Clinical Practice</i> , <b>2016</b> , 3, 303-305	2.2	5
113	Successful pallidotomy for post-hyperglycemic hemichorea-ballism. <i>Parkinsonism and Related Disorders</i> , <b>2019</b> , 61, 228-230	3.6	5
112	Improved Segmentation of the Intracranial and Ventricular Volumes in Populations with Cerebrovascular Lesions and Atrophy Using 3D CNNs. <i>Neuroinformatics</i> , <b>2021</b> , 19, 597-618	3.2	5
111	Parkinson's Disease and COVID-19: Do We Need to Be More Patient?. <i>Movement Disorders</i> , <b>2021</b> , 36, 277	7	5
110	Plasma near-infrared spectroscopy for diagnosis of idiopathic Parkinson's disease: the SPIN-PD study. <i>Biomarkers in Medicine</i> , <b>2015</b> , 9, 89-97	2.3	4
109	Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson disease. <i>Cmaj</i> , <b>2018</b> , 190, E50-E52	3.5	4
108	Comment on "Is it Useful to Classify PSP and CBD as Different Disorders?". <i>Movement Disorders Clinical Practice</i> , <b>2018</b> , 5, 564-565	2.2	4
107	Stem cell therapy for Parkinson's disease. <i>Annals of Neurology</i> , <b>2012</b> , 71, 283; author reply 284	9.4	4
106	Motor and non-motor fluctuations. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2007</b> , 84, 157-84	3	4
105	Rapidly progressive behavioral changes and parkinsonism in a 68-year-old man. <i>Movement Disorders</i> , <b>2004</b> , 19, 534-43	7	4
104	"Weight-holding tremor": an unusual task-specific form of essential tremor?. <i>Movement Disorders</i> , <b>1995</b> , 10, 228-9	7	4
103	Video-tutorial for the Movement Disorder Society criteria for progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , <b>2020</b> , 78, 200-203	3.6	4

102	The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation. <i>Parkinsonism and Related Disorders</i> , <b>2020</b> , 79, 121-126	3.6	4
101	Tracking the course of prodromal Parkinson's disease. <i>Brain</i> , <b>2017</b> , 140, 259-262	11.2	3
100	The evidence for multidisciplinary care in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , <b>2020</b> , 20, 539-549	4.3	3
99	Forecasts for the Attainment of Major Research Milestones in Parkinson's Disease. <i>Journal of Parkinsons Disease</i> , <b>2020</b> , 10, 1047-1055	5.3	3
98	Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency?. <i>Parkinsonism and Related Disorders</i> , <b>2020</b> , 71, 44-45	3.6	3
97	Infantile-onset hand dystonia with intellectual disability: Clues to mutations. <i>Neurology</i> , <b>2018</b> , 90, 333-335		3
96	Harnessing the power of placebos in movement disorders: Insights from Parkinson's disease in clinical research and practice. <i>Movement Disorders</i> , <b>2018</b> , 33, 1195-1203	7	3
95	Recurrent Impulse Control Disorder Associated with Rasagiline Treatment of Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , <b>2017</b> , 44, 447-448	1	3
94	Will New Genetic Techniques Like Exome Sequencing Obviate the Need for Clinical Expertise? No. <i>Movement Disorders Clinical Practice</i> , <b>2017</b> , 4, 39-41	2.2	3
93	Dystonic Pseudo Foot Drop. <i>Movement Disorders Clinical Practice</i> , <b>2015</b> , 2, 295-298	2.2	3
92	Effect of movement frequency on repetitive finger movements in patients with Parkinson's disease. <i>Movement Disorders</i> , <b>2010</b> , 25, 252; author reply 253	7	3
91	Progress in clinical neurosciences: a forum on the early management of Parkinson's disease. <i>Canadian Journal of Neurological Sciences</i> , <b>2005</b> , 32, 277-86	1	3
90	Essential palatal tremor. <i>Movement Disorders</i> , <b>2001</b> , 16, 1202-3	7	3
89	Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson's disease trial. <i>BMC Neurology</i> , <b>2021</b> , 21, 459	3.1	3
88	Movement Disorders: Diagnosis and Assessment <b>2008</b> , 293-325		3
87	Value of Clinical Signs in Identifying Patients with Scans without Evidence of Dopaminergic Deficit (SWEDD). <i>Journal of Parkinsons Disease</i> , <b>2020</b> , 10, 1561-1569	5.3	3
86	Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal study. <i>Parkinsonism and Related Disorders</i> , <b>2020</b> , 80, 127-132	3.6	3
85	Spinocerebellar Ataxia 40: Another Etiology Underlying Essential Tremor Syndrome. <i>Movement Disorders Clinical Practice</i> , <b>2021</b> , 8, 944-946	2.2	3

84	A Distinct EEG Marker of Celiac Disease-Related Cortical Myoclonus. <i>Movement Disorders</i> , <b>2021</b> , 36, 999-1005	3	3
83	Neither a Novel Tau Proteinopathy nor an Expansion of a Phenotype: Reappraising Clinicopathology-Based Nosology. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	3
82	Non-Dopaminergic Pathology of Parkinson's Disease	15-31	3
81	Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force - An Update.. <i>Movement Disorders</i> , <b>2022</b> , 37, 905-935	7	3
80	Isolated Abdominal Motor Seizures of Mesial Parietal Origin: Epileptic Belly Dancing?. <i>Movement Disorders Clinical Practice</i> , <b>2019</b> , 6, 396-399	2.2	2
79	Jumping to overcome freezing of gait while turning in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2019</b> , 64, 349-351	3.6	2
78	Age-Related Parkinsonian Signs in Microdeletion 22q11.2. <i>Movement Disorders</i> , <b>2020</b> , 35, 1239-1245	7	2
77	Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency? Response from the authors. <i>Parkinsonism and Related Disorders</i> , <b>2020</b> , 74, 80	3.6	2
76	Amantadine for Gait Dysfunction in Pantothenate Kinase-Associated Neurodegeneration. <i>Canadian Journal of Neurological Sciences</i> , <b>2019</b> , 46, 782-784	1	2
75	Hemiballism	1	2
74	Is there even such a thing as "idiopathic normal pressure hydrocephalus"?. <i>Annals of Neurology</i> , <b>2017</b> , 82, 1032	9.4	2
73	Pain and Paresthesia in Parkinson's Disease	2011, 315-332	2
72	Multiple system atrophy	2005, 623-662	2
71	Deep Bayesian networks for uncertainty estimation and adversarial resistance of white matter hyperintensity segmentation.. <i>Human Brain Mapping</i> , <b>2022</b> ,	5.9	2
70	Diagnosing functional neurological disorder: seeing the whole picture. <i>CNS Spectrums</i> , <b>2020</b> , 1-8	1.8	2
69	Interhemispheric pathways in agenesis of the corpus callosum and Parkinson's disease. <i>Brain Stimulation</i> , <b>2020</b> , 13, 360-362	5.1	2
68	Treatment of Palatal Tremor. <i>Current Clinical Neurology</i> , <b>2019</b> , 179-183	0.1	1
67	Commentary. <i>Movement Disorders</i> , <b>2013</b> , 28, 1806-7	7	1

66	In pursuit of prodromal Parkinson's disease. <i>Lancet Neurology, The</i> , <b>2015</b> , 14, 27-8	24.1	1
65	Dopamine Dysregulation Syndrome <b>2011</b> , 202-214		1
64	Anxiety Syndromes and Panic Attacks <b>2011</b> , 193-201		1
63	The Emerging Entity of Pre-Motor Parkinson's Disease <b>2011</b> , 93-104		1
62	Selected genetically engineered models relevant to human neurodegenerative disease <b>2005</b> , 176-195		1
61	Structural and functional magnetic resonance imaging in neurodegenerative diseases <b>2005</b> , 253-289		1
60	69-year-old man with gait disturbance and Parkinsonism. <i>Movement Disorders</i> , <b>2001</b> , 16, 548-61	7	1
59	Gait, Postural Instability, and Freezing 261-373		1
58	Reply to: "The Logic and Pitfalls of Parkinson's as Brain- Versus Body-First Subtypes". <i>Movement Disorders</i> , <b>2021</b> , 36, 786-787	7	1
57	Dream Enactment Behavior Disorder Associated with Pallido-Nigro-Luysian Degeneration and Tau Proteinopathy. <i>Movement Disorders Clinical Practice</i> , <b>2021</b> , 8, 594-599	2.2	1
56	Expectations of Benefit in a Trial of a Candidate Disease-Modifying Treatment for Parkinson Disease. <i>Movement Disorders</i> , <b>2021</b> , 36, 1964-1967	7	1
55	Early Clinical Predictors of Treatment-Resistant and Functional Outcomes in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , <b>2016</b> , 3, 53-58	2.2	1
54	Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease. <i>Movement Disorders</i> , <b>2021</b> , 36, 171-177	7	1
53	DYT-TUBB4A (DYT4 Dystonia): New Clinical and Genetic Observations. <i>Neurology</i> , <b>2021</b> , 96, e1887-e1897	6.5	1
52	Suggestibility as a valuable criterion for laboratory-supported definite functional movement disorders. <i>Clinical Neurophysiology Practice</i> , <b>2021</b> , 6, 103-108	3.8	1
51	Bilingualism in Parkinson's disease: Relationship to cognition and quality of life. <i>Journal of Clinical and Experimental Neuropsychology</i> , <b>2021</b> , 43, 199-212	2.1	1
50	The Discovery of $\alpha$ -Synuclein in Lewy Pathology of Parkinson's Disease: The Inspiration of a Revolution. <i>Movement Disorders Clinical Practice</i> , <b>2021</b> , 8, 1189-1193	2.2	1
49	Contribution of rare variant associations to neurodegenerative disease presentation. <i>Npj Genomic Medicine</i> , <b>2021</b> , 6, 80	6.2	1



48	Association of apolipoprotein E variation with cognitive impairment across multiple neurodegenerative diagnoses. <i>Neurobiology of Aging</i> , <b>2021</b> , 105, 378.e1-378.e9	5.6	1
47	Neuroimaging Pearls from the MDS Congress Video Challenge. Part 1: Genetic Disorders.. <i>Movement Disorders Clinical Practice</i> , <b>2022</b> , 9, 297-310	2.2	0
46	Neuroimaging Pearls from the MDS Congress Video Challenge. Part 2: Acquired Disorders.. <i>Movement Disorders Clinical Practice</i> , <b>2022</b> , 9, 311-325	2.2	0
45	Call the Plumber: Impaired Meningeal Lymphatic Drainage in Parkinson's Disease. <i>Movement Disorders</i> , <b>2021</b> , 36, 1125	7	0
44	Preferences for Communication About End-of-Life Care in Atypical Parkinsonism. <i>Movement Disorders</i> , <b>2021</b> , 36, 2116-2125	7	0
43	Movement Disorders Associated with Hypogonadism. <i>Movement Disorders Clinical Practice</i> , <b>2021</b> , 8, 997-1011	10.11	0
42	Botulinum Toxin-Associated Prolonged Remission of Idiopathic Cervical Dystonia. <i>Canadian Journal of Neurological Sciences</i> , <b>2021</b> , 1-5	1	0
41	Is clinical assessment enough? Moving towards early differentiation of neurodegenerative parkinsonisms. <i>Brain</i> , <b>2021</b> , 144, 1040-1042	11.2	0
40	Short-term deceleration capacity of heart rate: a sensitive marker of cardiac autonomic dysfunction in idiopathic Parkinson's disease. <i>Clinical Autonomic Research</i> , <b>2021</b> , 31, 729-736	4.3	0
39	Irreversible extreme freezing of gait after dopamine agonist withdrawal. <i>Clinical Case Reports (discontinued)</i> , <b>2021</b> , 9, e04712	0.7	0
38	Case of a Man with Hemichorea and Behavioral Changes: "A Red Herring".. <i>Movement Disorders Clinical Practice</i> , <b>2022</b> , 9, 501-507	2.2	0
37	Reply to "Studying reproducibility of data-driven Parkinson's disease subtypes". <i>Parkinsonism and Related Disorders</i> , <b>2019</b> , 66, 245-246	3.6	
36	Lessons learned: neuroprotective trials in Parkinson's disease	265-279	
35	The Clinical Spectrum of Functional/Psychogenic Dystonia	217-223	
34	Dancing Dorsal Quadrilaterals-Organic or Functional?-Reply. <i>JAMA Neurology</i> , <b>2019</b> , 76, 985-986	17.2	
33	Reply to Drs. Kurlan, Fasano, and Evans: A clinically useful definition of stereotypies. <i>Movement Disorders</i> , <b>2013</b> , 28, 405-6	7	
32	Reply to letter: Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. <i>Movement Disorders</i> , <b>2013</b> , 28, 408	7	
31	Overview of the Medical Treatment of the Non-Motor and Non-Dopaminergic Features of Parkinson's Disease	2011, 394-408	

- 30 Psychosis in Parkinson's Disease **2011**, 170-182
- 29 Depression in Parkinson's Disease **2011**, 183-192
- 28 Neurobiology of Impulse Control Disorders in Parkinson's Disease **2011**, 215-232
- 27 Therapy of the Motor Features of Parkinson's Disease. *Blue Books of Neurology*, **2010**, 34, 252-272
- 26 Reply: The variability of levodopa response in Parkinson's disease: Is sensitization reversible?. *Movement Disorders*, **2008**, 23, 925-925 7
- 25 Corticobasal degeneration **2005**, 682-696
- 24 Neurophysiology of Parkinson's disease, levodopa-induced dyskinesias, dystonia, Huntington's disease and myoclonus **2005**, 227-250
- 23 Approach to the patient presenting with parkinsonism **2005**, 551-560
- 22 Current and potential treatments of Parkinson's disease **2005**, 612-622
- 21 Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders.. *Frontiers in Psychiatry*, **2022**, 13, 816465 5
- 20 Pathophysiology of the Internal Segment of the Globus Pallidus in Parkinson's Disease. *Advances in Behavioral Biology*, **2002**, 15-21
- 19 Sleepiness and Sleep Attacks in Parkinson's Disease. *Advances in Behavioral Biology*, **2002**, 385-390
- 18 Psychogenic Dystonia. *Medical Psychiatry*, **2006**, 277-288
- 17 Isolated Ear Clicks with Partial Voluntary Control. *Tremor and Other Hyperkinetic Movements*, **2020**, 10, 55 2
- 16 Assessment of Non-Motor Features of Parkinson's Disease: Scales and Rating Tools 111-125
- 15 Neuropsychologic Features of Parkinson's Dementias 145-152
- 14 Sexual Dysfunction 296-303
- 13 Prospects for Neuroprotective Therapies that can Modulate Non-Dopaminergic Features in Parkinson's Disease 455-461

- 12 Surgery for Non-Dopaminergic and Non-Motor Features of Parkinson's Disease 409-415
- 11 Functional Anatomy of the Motor and Non-Motor Circuitry of the Basal Ganglia 32-55
- 10 Animal Models of Parkinson's Disease: The Non-Motor and Non-Dopaminergic Features 79-92
- 9 Clinical Trial Measures of the Non-Motor Features of Parkinson's Disease 126-133
- 8 Treatment of Dementia Associated with Parkinson's Disease 163-169
- 7 Parkinsonism **2012**, 2326-2333
- 6 Psychogenic dystonia **2012**, 307-319
- 5 Initiating pharmacotherapy in early Parkinson's disease. *Lancet Neurology, The*, **2020**, 19, 643-644 24.1
- 4 Teaching Video NeuroImage: "Weighing" in on an Unusual Tremor. *Neurology*, **2021**, 97, e970-e971 6.5
- 3 Hyperglycemic hemichorea presenting with normal MRI and striatal hyperdensity on CT. *Neurological Sciences*, **2021**, 42, 4341-4343 3.5
- 2 Inhaled Levodopa as a Potential Treatment for Diphasic Dyskinesia. *Movement Disorders*, **2021**, 36, 265-266
- 1 Investigating the contribution of white matter hyperintensities and cortical thickness to empathy in neurodegenerative and cerebrovascular diseases.. *GeroScience*, **2022**, 1 8.9